Русский
To the issue of the relevance of the development of new anti-tuberculosis drugs
DOI: https://dx.doi.org/10.18565/pharmateca.2022.10.10-15
A.Yu. Savchenko, G.V. Ramenskaya, V.G. Kukes, M.S. Burenkov
1) Scientific Center for Biomedical Technologies of the Federal Medical and Biological Agency of Russia, Moscow Region, Russia; 2) Sechenov University, Moscow, Russia; 3) Branch “Clinical Pharmacology”, Scientific Center for Biomedical Technologies of the Federal Medical and Biological Agency of Russia, Moscow, Russia; 4) JSC Pharmsintez, Moscow, Russia
In order to overcome multidrug-resistant, extensively drug-resistant and complete drug-resistant TB (MDR-TB, XDR-TB and CDR-TB, respectively), a number of new tuberculosis drugs are being studied and introduced around the world. The group of diarylquinolines is defined as one of the most promising in terms of anti-tuberculosis activity. Along with foreign ones (bedaquiline, delamanid), domestic developments (perchlozone) are being introduced into the practice of M/XDR-TB treatment. At the same time, there are reports of identified resistance of Mycobacterium tuberculosis to bedaquiline, which is relatively recently used to treat patients with M/XDR-TB. These prerequisites underlie the relevance of the development and introduction of new tuberculosis drugs in Russia, in particular, a new drug from the group of diarylquinolines with the working name thiozonide is at the stage of studying the tolerability, efficacy and safety
About the Autors
Corresponding author: Alla Yu. Savchenko, Laboratory of Pharmacomodeling, Scientific Center for Biomedical Technologies of the FMBA of Russia, Moscow Region, Russia; alursav@mail.ru
